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INTRODUCTION

OUTCOME AND FOLLOW-UP

Peripartum cardiomyopathy (PPCM), also known as
postpartum cardiomyopathy, is an infrequent cause of
systolic heart failure that can affect women in the last
month of pregnancy and up to five months after delivery.
While PPCM is a type of dilated cardiomyopathy, the
etiology of this condition remains largely unknown. 1
Given the infrequency with which PPCM is encountered
and the potential for this condition to be fatal, proper
diagnosis and management is critical for reducing
maternal and fetal complications, as well as assessing
the safety of future pregnancies.

The patient was initially treated with diuretics, vasodilators,
beta-blockers, and bronchodilators. Despite these
interventions, her condition worsened, and she was
transferred to the Intensive Care Unit (ICU) for respiratory
distress, ultimately requiring non-invasive respiratory
assistance with bilevel positive airway pressure (BiPAP).
Following lack of clinical improvement over 24 hours
and a worsening LVEF of <20%, she was transferred to
our institution and admitted to the cardiac ICU. An
ACE-inhibitor and a prophylactic dose of heparin (5000
units subcutaneous injections every 8 hours) were
added to her medical regimen due to her risk factors for
venous thromboembolism (low ejection fraction and
recent pregnancy). She was also treated with aggressive
diuresis. After a few days, her dyspnea, lower extremity
edema, and pulmonary congestion improved. Once
hemodynamically stable, she was transferred to a
general medical/cardiology floor and was subsequently
discharged with a wearable defibrillator, angiotensin
receptor blocker, anticoagulant, diuretics, and
instructions to follow-up with outpatient cardiology. The
goal was to start her on Entresto (sacubitril/valsartan),
which works well in patients with heart failure with
reduced ejection fraction. However, the use of Entresto
and an ACE-inhibitor is contraindicated, and a washout
period of 36 hours is required between administration of
the two medications.2 The cardiology team also planned
for at least three months of prophylactic anticoagulation. The patient was discharged home with warfarin
2.5 mg PO every other day, alternating with 5.0 mg PO
on the off-days until she became therapeutic.

CASE PRESENTATION
A 33-year-old gravida 3, para 1, abortus 1 (G3P1011) at
39 weeks and 5 days of gestation presented to labor
and delivery with a complaint of new-onset headache
and vaginal bleeding that began earlier that morning.
Her medical and social histories were significant for
chronic hypertension and a one-half pack per day
smoking history. Despite persistently elevated blood
pressure greater than 140/90 mmHg, the remainder of
an evaluation for preeclampsia was negative. Clinical
assessment of her vaginal bleeding was suspicious for
abruptio placentae, ultimately leading to the decision to
proceed with induction of labor. Subsequent arrest of
dilatation and concerns for worsening abruption led to
cesarean delivery of a live male. After an uncomplicated
recovery, the patient was discharged home on the
second postoperative day with a narcotic analgesic and
a beta blocker, which was started during her pregnancy
and continued as treatment for her chronic hypertension.
On the sixth postoperative day, she presented to the
emergency department with severe shortness of breath.
Physical examination was remarkable for tachycardia,
bilateral basilar crackles on chest auscultation, and 1+
edema in her lower extremities. Chest CTA demonstrated
no evidence of pulmonary embolism and cardiac MRI
showed no evidence of myocardial scarring, fibrosis, or
pericarditis. Her NT-proBNP (22,555 pg/ml) and cardiac
troponin I levels (0.172 ng/ml) were significantly
elevated, and she was diagnosed clinically with acute
heart failure. Right heart catheterization and tissue
biopsy were considered, but not performed. An
echocardiogram revealed an estimated left ventricular
ejection fraction (LVEF) of 25 to 30%, consistent with
the diagnosis of PPCM.

DISCUSSION
PPCM is a serious complication of pregnancy with an
incidence that varies geographically, possibly due to
socioeconomic and genetic factors. For example, the
highest rates of PPCM are reported in Haiti (33 per
10,000 live births), whereas the incidence in the United
States is estimated to be 4.84 per 10,000 live births.1
While the etiology of the condition is unknown, multiple
hypotheses have been proposed including a final
common pathway that increases oxidative stress and
cleaves prolactin into a 16kDA fragment that results in
endothelial damage and myocardial dysfunction. An
inflammatory cascade of cytokines (tumor necrosis
factor-alpha and interleukin-6) is signaled, which further
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precipitates the condition. Specifically, altered prolactin
processing results in a pro-apoptotic, anti-angiogenic,
pro-inflammatory, and cardiotoxic 16kDA isoform. 3
Other small studies have demonstrated an increased
prevalence of PPCM with myocarditis and found the
presence of parvovirus B19, human herpes virus-6, and
human cytomegalovirus (CMV) in myocardial biopsy
samples of PPCM patients.4 Known risk factors of PPCM
include age greater than 30 years, multiple gestations,
non-Hispanic African American race, maternal cocaine
abuse, and history of preeclampsia, eclampsia, HELLP
syndrome, and postpartum hypertension.1,5
The signs and symptoms associated with PPCM are
similar to that of third-trimester pregnancy, so diagnosis
is often delayed. Patients often present with symptoms
secondary to volume overload — including dyspnea,
cough, orthopnea, paroxysmal nocturnal dyspnea, and
pedal edema — which overlap with symptoms that may
be observed in normal pregnancy.5 Common physical
findings include elevated jugular venous pressure, a
displaced apical impulse, and a third heart sound which
are similarly non-specific since these are also seen in
other forms of heart failure. PPCM is therefore a diagnosis
of exclusion and is based on three clinical criteria:
manifestation of heart failure toward the end of
pregnancy or during the few months following delivery,
absence of another identifiable cause of heart failure,
and LVEF < 45%.6 In this case, despite the patient’s history
of hypertension and smoking, her presentation and
workup satisfied all three criteria.
Typically, PPCM is managed similarly to that of acute LV
systolic heart failure in non-pregnant women with the
exception that medications contraindicated during
pregnancy (such as angiotensin converting enzyme
inhibitors, angiotensin II receptor blockers, and
aldosterone antagonists) are avoided. First-line medical
therapy includes digoxin, loop diuretics, hydralazine,
nitrates, and beta-blockers.5 Although pregnancy is a
hypercoagulable state, it is not recommended that all
peripartum patients receive anticoagulation. However,
those with risk factors for venous thromboembolism,
such as a low ejection fraction (specifically LVEF < 35%)
— which is associated with an increased risk of LV
thrombus — and recent pregnancy should receive
anticoagulation with a prophylactic dose of heparin.7
Unless patients are acutely decompensating, full-term
vaginal deliveries are preferred because of the lower
rates of complications such as endometritis and
pulmonary embolism. Regional anesthesia (epidural or
spinal) can reduce pain and is recommended over
general anesthesia, which is associated with myocardial
depression. Mothers are encouraged to breastfeed as
long as they are hemodynamically stable and there are
no contraindications with their medications.8
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With regards to follow-up, 20-60% of PPCM patients
have complete recovery of LVEF by six months to five
years. However, cardiac transplantation, left ventricular
assist devices, and implantable cardioverter defibrillators
can be considered for women who experience
progressive left ventricular dysfunction despite adequate
medical therapy and recovery time.7,8 Patients who have
persistent LVEF < 50% or LVEF ≤ 25% at the time of
diagnosis should avoid future pregnancies due to
the increased risk of heart failure complications,
thromboembolic events, and death.6 For these patients,
a discussion about contraception is imperative.
In general, all postpartum patients should avoid estrogencontaining products due to its thrombogenic potential
and interference with breastfeeding. Abstinence or
sterilization should be heavily counseled for in PPCM
patients, but long-acting reversible contraception
(LARC) such as progestin-containing intrauterine
devices (IUDs)/implants and the copper IUD are also an
option. Patients or their partners may also undergo
sterilization procedures such as bilateral tubal ligation
or vasectomy. 6 Ultimately, the development of a
treatment plan involves the consultation of internists,
high-risk obstetricians (maternal fetal medicine), and
anesthesiologists.

KEY POINTS
• This case illustrates the potential for PPCM and acute
decompensation in an otherwise healthy patient and
the value of recognizing the signs and symptoms
associated with this condition, which can be fatal.
• PPCM is a diagnosis of exclusion based on three
clinical criteria, and treatment is similar to that of acute
systolic LV heart failure.
• Long-term prognosis of PPCM ranges anywhere from
full recovery to requiring heart transplantation.
• An understanding of the etiology of PPCM and identification of preventative measures — which have not
been thoroughly explored — is clinically significant for
obstetricians, cardiologists, anesthesiologists, and
neonatologists who may all be involved in either
maternal or fetal care.
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